¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"amino acids, cyclic"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 6 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • cyclic neutropenia
    ÁÖ±âÁß¼º±¸°¨¼Ò(Áõ)
  • cyclic parturition
    ÁÖ±âºÐ¸¸
  • cyclic periodicity
    ¼øÈ¯Áֱ⼺
  • cyclic schizophrenia
    ¼øÈ¯ÇüÁ¤½ÅºÐ¿­º´
  • cyclic strabismus
    ÁÖ±â»ç½Ã
  • cyclic vomiting
    Áֱ⼺±¸Åä
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 9 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • cyclic hematopoiesis
    Áֱ⼺Á¶Ç÷
  • cyclic hemorrhage
    ÁÖ±âÃâÇ÷
  • cyclic hydrocarbon
    °í¸®Çüźȭ¼ö¼Ò
  • cyclic neutropenia
    ÁÖ±âÈ£Áß¼º¹éÇ÷±¸°¨¼ÒÁõ
  • cyclic parturition
    ÁÖ±âºÐ¸¸
  • cyclic periodicity
    ¼øÈ¯Áֱ⼺
  • cyclic schizophrenia
    ¼øÈ¯Á¤½ÅºÐ¿­º´
  • cyclic spasm
    Áֱ⿬Ãà
  • cyclic strabismus
    ÁÖ±â»ç½Ã
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 6 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • amino group
    ¾Æ¹Ì³ë±â(¡­Ðñ).
  • amino sugar
    ¾Æ¹Ì³ë´ç(¡­ÓØ).
  • amino terminal
    ¾Æ¹Ì³ëÁ¾´Ü<¸»´Ü>.
  • aromatic amino acid
    ¹æÇâÁ·¾Æ¹Ì³ë»ê.
  • arormatic amino acid
    ¹æÇâÁ·¾Æ¹Ì³ë»ê
  • renal amino aciduria
    ½Å¼º ¾Æ¹Ì³ë»ê´¢
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • amino compound
    ¾Æ¹Ì³ëÈ­ÇÕ¹°(¡­ûùùêÚª).
  • amino group
    ¾Æ¹Ì³ë±â(¡­Ðñ).
  • amino sugar
    ¾Æ¹Ì³ë´ç(¡­ÓØ).
  • amino terminal
    ¾Æ¹Ì³ëÁ¾´Ü<¸»´Ü>.
  • aromatic amino acid
    ¹æÇâÁ·¾Æ¹Ì³ë»ê.
  • arormatic amino acid
    ¹æÇâÁ·¾Æ¹Ì³ë»ê
  • branched chain amino acid
    ºÐÁö¼â¾Æ¹Ì³ë»ê
  • essential amino acid
    Çʼö¾Æ¹Ì³ë»ê
  • essential amino acid
    Çʼö(ù±âÎ)¾Æ¹Ì³ë»ê
  • excitatory amino acid
    ÈïºÐ¼º ¾Æ¹Ì³ë»ê
  • gamma amino butyric acid =GABA
    °·¸¶¾Æ¹Ì³ëºêƼ¸£»ê.
  • gamma amino butyric acid =GABA
    °¨¸¶¾Æ¹Ì³ëºÎƼ¸£»ê.
  • metabolic defect of amino acid (alkaptonuria)
    ¾Æ¹Ì³ë»ê´ë»ç°áÇÔ(¾Ëİſ´¢Áõ)
  • nonessential amino acid
    ºñÇʼö¾Æ¹Ì³ë»ê
  • renal amino aciduria
    ½Å¼º ¾Æ¹Ì³ë»ê´¢
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • cyclic photophosphorylation
    ¼øÈ¯ ±¤ÀλêÈ­(âàü»ÎÃìÝß«ûù)
  • cyclic symmetry
    "°í¸®´ëĪ(Óßöà), (ÔÒ) rotational symmetry"
  • "uanosine-3', 5'-cyclic monophosphate"
    "±¸¾Æ³ë½Å-3`,5'-°í¸® ÀÏÀλê(ìé×òß«)"
  • nucleoside cyclic monophosphate
    °í¸® ÀÏÀλê(ìé×òß«) ´©Å¬¸®¿À»çÀ̵å
  • acidic amino acid
    »ê¼º(ß«àõ)¾Æ¹Ì³ë»ê(ß«)
  • active amino acid
    Ȱ¼º(üÀàõ)¾Æ¹Ì³ë»ê (ß«)
  • alpha amino acid
    ¾ËÆÄ¾Æ¹Ì³ë»ê(ß«)
  • amino acetic acid
    ¾Æ¹Ì³ë¾Æ¼¼Æ®»ê(ß«)
  • amino acid
    ¾Æ¹Ì³ë»ê(ß«)
  • amino acid accepting RNA
    ¾Æ¹Ì³ë»ê(ß«) ¼ö³³(áôÒ¡)RNA
  • amino acid activating enzyme
    ¾Æ¹Ì³ë»ê(ß«) Ȱ¼ºÈ­(üÀàõûù) È¿¼Ò(ý£áÈ)
  • amino acid activation
    ¾Æ¹Ì³ë»ê(ß«) Ȱ¼ºÈ­(üÀàõûù)
  • amino acid analysis
    ¾Æ¹Ì³ë»ê(ß«) ºÐ¼®(ÝÂà°)
  • amino acid analyzer
    ¾Æ¹Ì³ë»ê(ß«) ºÐ¼®±â(ÝÂà°Ðï)
  • amino acid arm
    ¾Æ¹Ì³ë»ê ÆÈ
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
VLCFA Very Long Chain Fatty Acids
poly-IC, poly-I:C copolymer of polyinosinic and polycytidylic acids; synthetic RNA polymer
TBA tertiary butylacetate; testosterone-binding affinity; tetrabutylammonium; thiobarbituric acid; to be...
TFA total fatty acids; transverse fascicular area; triangular fibrocartilage; trifluoroacetic acid
TSBA total serum bile acids
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
cyclic GMP Cyclic guanosine monophosphate
HETE's Mono-hydroxy-eicosatetraenoic acids
LCP Long Chain Polyunsaturated fatty acids
LCFA Long chain fatty acids
MCFA Medium-chain fatty acids
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 8 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • arormatic amino acid
    ¹æÇâÁ· ¾Æ¹Ì³ë»ê
  • D-amino acid polymer
    D-¾Æ¹Ì³ë»ê ÁßÇÕü
    D-amino »ê¿¡¼­ ÇÕ¼ºÇÏ¿© ¸¸µé¾îÁø Ç׿ø¼ºÀÌ °­ÇÑ ÆéŸÀ̵å, ¶Ç´Â Æú¸® ÆéŸÀ̵å.
  • essential amino acid
    Çʼö ¾Æ¹Ì³ë»ê
    ´Ü¹éÁúÀÇ ±âº» ±¸¼º ´ÜÀ§. ´Ü¹éÁúÀº ü³»¿¡¼­ ¾Æ¹Ì³ë»êÀ¸·Î ºÐÇØµÇ°í ³ª¼­ Èí¼ö, ÀÌ¿ëµÈ´Ù. µû¶ó¼­ ´Ü¹éÁúÀÇ ¿µ¾ç°¡´Â ±× ¼Ó¿¡ ÇÔÀ¯µÇ´Â ¾Æ¹Ì³ë»êÀÇ Á¾·ù¿Í ¾ç¿¡ ÀÇÇÏ¿© Á¤ÇØÁø´Ù. ¾Æ¹Ì³ë»êÀº µ¿¹°ÀÇ Ã¼³»¿¡¼­ ´Ù¸¥ ¾Æ¹Ì³ë»êÀ¸·ÎºÎÅÍ ¸¸µé¾îÁö´Â °Í°ú, ü³»¿¡¼­´Â ÇÕ¼ºµÇÁö ¾Ê°í À½½ÄÀ¸·Î ¼·ÃëµÇ¾î¾ß ÇÏ´Â °ÍÀÌ ÀÖ´Ù. µû¶ó¼­ ¼·ÃëÇÏÁö ¾ÊÀ¸¸é ¿ÏÀüÇÑ ´Ü¹éÁúÀÌ µÇÁö ¾Ê´Â´Ù. ÀÌ·¸°Ô ü³»¿¡¼­ ÇÕ¼ºÇÒ ¼ö ¾ø´Â ¾Æ¹Ì³ë»êÀ» Çʼö ¾Æ¹Ì³ë»ê ¶Ç´Â ºÒ°¡°á ¾Æ¹Ì³ë»êÀ̶ó°í ÇÑ´Ù. Çʼö ¾Æ¹Ì³ë»êÀÇ Á¾·ù´Â µ¿¹°ÀÇ Á¾·ù³ª ¼ºÀå ½Ã±â¿¡ µû¶ó ´Ù¸£Áö¸¸, ¼ºÀÎÀÇ °æ¿ì¿¡´Â ´ÙÀ½ÀÇ 8Á¾ÀÌ´Ù. À̼ҷù½Å, ·ù½Å, ¸®½Å, Æä´Ò¾Ë¶ó´Ñ, ¸ÞƼ¿À´Ñ, Æ®·¹¿À´Ñ, Æ®¸³ÅäÆÇ, ¹ß¸°ÀÌ´Ù. ¾î¸°¾ÆÀÌÀÇ °æ¿ì¿¡´Â ¿©±â¿¡ È÷½ºÆ¼µòÀÌ ´õÇØÁø´Ù.
  • metabolic defect of amino acid
    ¾Æ¹Ì³ë»ê ´ë»ç °áÇÔ
    ¾Ëİſ ´¢Áõ.
  • para- : ºÎ, ÁÖÀ§, ¹æ, ±Ù, ±Ù»ç, ¿ø ¹× ÀÌ µîÀÇ ¶æÀ» ³ªÅ¸³»´Â Á¢µÎ¾î.

    para-amino salicylic acid

    ÆÄ¶ó-¾Æ¹Ì³ë »ì¸®½Ç »ê
    ÇÕ¼ºµÈ Ç×°áÇÙ ¾àÀ¸·Î Ç×±Õ ÀÛ¿ëÀº °áÇÙ ±Õ¿¡ ƯÀÌÀûÀÌ¸ç ´Ù¸¥ º´¿ø ±Õ¿¡ ÀÛ¿ëÇÏÁö ¾Ê´Â´Ù. È­ÇÐ ±¸Á¶´Â »ì¸®½Ç »ê°ú À¯»çÇϳª ÁßÃß ½Å°æ°è¿¡ ´ëÇÑ ÀÛ¿ëÀº °ÅÀÇ ¾ø´Ù. ÀÛ¿ë ±âÀüÀº ¸íÈ®ÇÏÁö ¾ÊÀ¸¸ç ´ë»ç ±æÇ×Á¦, È£Èí »ê¼Ò ÀúÇØ¼³ÀÌ ÀÖ´Ù. ½ÃÇè°ü ³»ÀÇ Ç×±Õ ÀÛ¿ëÀº °­ÇÏÁö¸¸ Ç׿°Àº ¾ÆÀ̼ҳªÀ̾ÆÁö, ½ºÆ®·¾Å丶À̽ź¸´Ù ¾à°£ ¾àÇÏ¸ç ´ë·®ÀÇ º¹¿ëÀ» ¿äÇÑ´Ù. ½ºÆ®·¾Å丶À̽ź¸´Ù ³»¼º ÃâÇöÀÌ ´Ê´Ù. ´Üµ¶º¸´Ù ½ºÆ®·¾Å丶À̽Å, ¾ÆÀ̼ҳªÀ̾ÆÁöµå¿ÍÀÇ º´¿ëÀº È¿°ú Áõ°­°ú ³»¼º ¹ßÇöÀÇ Áö¿¬È­¸¦ ³ë¸°´Ù. µ¶¼ºÀº ÀÛÀ¸¸ç ºÎÀÛ¿ëÀÇ ÁÖµÈ °ÍÀº ¼ÒÈ­°ü¿¡ ´ëÇÑ ±¹¼Ò Àڱؿ¡ ÀÇÇÑ °Í
  • renal amino aciduria
    ½Å¼º ¾Æ¹Ì³ë»ê´¢
  • sulfur-containing amino acid
    Ȳ ÇÔÀ¯ ¾Æ¹Ì³ë»ê
  • vasoactive amino
    Ç÷°ü Ȱ¼º ¾Æ¹Î
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
cyclic AMP-dependent protein kinase Enzymes which attach phosphate groups to the serine or tyrosine amino acids on proteins as a means of regulating the proteins' activity in metabolic reactions.
(09 Oct 1997)
cyclic AMP-dependent protein kinases <enzyme> A group of enzymes that are dependent on cyclic AMP and catalyze the phosphorylation of serine or threonine residues on proteins.
Registry number: EC 2.7.10.-
(12 Dec 1998)
cyclic AMP receptor protein A transcriptional regulator in prokaryotes which, when activated by binding cyclic AMP, acts at several promoters. Cyclic AMP receptor protein was originally identified as a catabolite gene activator protein. It was subsequently shown to regulate several functions unrelated to catabolism, and to be both a negative and a positive regulator of transcription. Cell surface cyclic AMP receptors are not included (cyclic AMP receptors), nor are the eukaryotic cytoplasmic cyclic AMP receptor proteins, which are the regulatory subunits of cyclic AMP-dependent protein kinases.
(12 Dec 1998)
cyclic cmp <chemical> Cytidine cyclic 3',5'-(hydrogen phosphate). It is formed in mammalian tissue by the enzymatic conversion of cytidine triphosphate and may play a role in the bioregulation of proliferation of normal and malignant cells.
Chemical name: Cytidine, cyclic 3',5'-(hydrogen phosphate)
(12 Dec 1998)
cyclic compound Any compound in which the constituent atoms, or any part of them, form a ring. Used mainly in organic chemistry where: 1) numerous compound's contain rings of carbon atoms (carbocyclic compound's) or carbon atoms plus one or more atoms of other types (heterocyclic compound's), usually nitrogen, oxygen, or sulfur; 2) where the atoms in the ring are all of the same element (homocyclic or isocyclic compound); 3) where the ring is saturated or contains nonconjugated double bonds (alicyclic compound), the compound is similar in properties to the corresponding acyclic compound (e.g., cyclohexane resembles hexane); 4) where the ring contains conjugated double bonds in a closed loop in which there are 4n + 2 (where n is an integer) delocalised &pi; electrons (Huckel's rule) (aromatic compound; e.g., benzene, pyridine), it is more stable than the corresponding saturated ring and exhibits unusual chemical properties characteristic of itself and not of other types of rings or of acyclic compound's. These aromatic compounds have the ability to sustain an induced ring current.
Synonym: closed chain compound, ring compound.
(05 Mar 2000)
cyclic esotropia Periodic convergent strabismus often occurring every 48 hours.
Synonym: alternate day strabismus.
(05 Mar 2000)
cyclic GMP <molecular biology> 3'5' cyclic ester of GMP. A second messenger generated by guanylyl cyclase.
See: ANP, Nitric oxide.
(18 Nov 1997)
cyclic GMP-dependent protein kinases <enzyme> A group of enzymes that are dependent on cyclic GMP and catalyses the phosphorylation of serine or threonine residues of proteins.
Registry number: EC 2.7.10.-
(12 Dec 1998)
cyclic GMP sensitive 3'-exoribonuclease <enzyme> Degradation of newly synthesised RNA in cells of bacillus brevis is mediated primarily by above enzyme
Registry number: EC 3.1.14.-
Synonym: cgmp-exoribonuclease
(26 Jun 1999)
cyclic guanosine monophosphate A cyclic version of the nucleotide guanosine monophosphate. It plays a role in communicating vision from the eyes to the brain.
(09 Oct 1997)
cyclic haematopoiesis An autosomal recessive, inherited immunodeficiency of gray collie dogs characterised by overwhelming recurrent bacterial infections, bleeding, and coat colour dilution.
Synonym: gray collie syndrome.
(05 Mar 2000)
cyclic imp <chemical> Inosine cyclic 3',5'-(hydrogen phosphate). An inosine nucleotide which acts as a mild inhibitor of the hydrolysis of cyclic AMP and cyclic GMP and as an inhibitor of cat heart cyclic AMP phosphodiesterase.
Chemical name: Inosine, cyclic 3',5'-(hydrogen phosphate)
(12 Dec 1998)
cyclic inositol phosphate 1, 2 cyclic derivatives of inositol phosphatide that are invariably formed during enzymic hydrolysis of phosphatidyl inositol species. Have been proposed as second messengers in hormone activated pathways.
(18 Nov 1997)
cyclic neutropenia Neutropenia recurring at regular intervals (14 to 45 days), in association with various types of infectious diseases, e.g., stomatitis, cutaneous ulcers, furuncles, arthritis, and others.
Synonym: cyclic neutropenia.
(05 Mar 2000)
cyclic nucleotide A nucleoside monophosphate in which the phosphoryl group is linked twice to the sugar moiety; e.g., adenosine 3',5'-cyclic monophosphate (cAMP).
(05 Mar 2000)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á